The Selective Norepinephrine Reuptake Inhibitor Antidepressant Reboxetine: Pharmacological and Clinical Profile
- 1 March 2004
- journal article
- review article
- Published by Wiley in CNS Drug Reviews
- Vol. 10 (1), 23-44
- https://doi.org/10.1111/j.1527-3458.2004.tb00002.x
Abstract
Reboxetine is the first commercially available norepinephrine reuptake inhibitor developed specifically as a first line therapy for major depressive disorder. In vitro and in vivo pharmacological studies indicated that reboxetine methanesulphonate has high affinity and selectivity for the human norepinephrine transporter over the serotonin and dopamine transporters. Pharmacological specificity is further demonstrated by the absence of affinity for 45 transmitter receptors and CNS targets. Pharmacokinetic studies demonstrated that reboxetine is suitable for twice daily administration (8-10 mg/day) and that it exhibits minimal drug-drug interactions. The starting dose of reboxetine should be reduced in the elderly, in patients with renal or hepatic impairment, or in patients receiving potent CYP3A inhibitors. A total of 20 phase II/III clinical studies comprising placebo-controlled, active comparator-controlled and open-label uncontrolled studies in both short-term and long-term treatment of major depression have been conducted. In the treatment of major depression, reboxetine was superior to placebo in 5 of 12 short- or long-term placebo-controlled studies and was comparable in efficacy to active comparators in 3 out of 3 active-controlled studies. Unlike conventional tricyclic antidepressants (TCAs), reboxetine had only minimal sedative and cardiovascular liabilities, probably due to increased pharmacological specificity of reboxetine as compared with TCAs. Unlike serotonin reuptake inhibitors, this selective and specific norepinephrine reuptake inhibitor demonstrated a distinct side-effect profile with diminishing sexual dysfunction and GI side effects. The availability of this agent has afforded patients suffering from major depressive disorder a new class of agents to combat the debilitating consequence of this psychiatric disease. The demonstrated pharmacological specificity of this compound has provided the psychopharmacology community with a tool to elucidate the role of norepinephrine in brain functions. Testing this agent in different animal models has enabled the exploration of the role of modulation of norepinephrine tone in the therapy of CNS disorders beyond depression.Keywords
This publication has 129 references indexed in Scilit:
- Norepinephrine but not Serotonin Reuptake Inhibitors Enhance Theta and Gamma Activity of the Septo-Hippocampal SystemNeuropsychopharmacology, 2002
- Influence of Reboxetine on Salivary MHPG Concentration and Cognitive Symptoms Among Patients with Alcohol-Related Korsakoff's SyndromeNeuropsychopharmacology, 2002
- ‘New’ and ‘old’ antidepressants: All equal in the eyes of the lore?The British Journal of Psychiatry, 2001
- Pharmacokinetics of Reboxetine in Volunteers with Hepatic ImpairmentClinical Drug Investigation, 2000
- Pharmacokinetics of Single‐Dose Reboxetine in Volunteers with Renal InsufficiencyThe Journal of Clinical Pharmacology, 2000
- Activity of Serotonergic Neurons in Behaving AnimalsNeuropsychopharmacology, 1999
- Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomesLife Sciences, 1993
- The use of tryptophan depletion to evaluate central serotonin function in depression and other neuropsychiatric disordersInternational Clinical Psychopharmacology, 1993
- Noradrenergic modulation of midbrain dopamine cell firing elicited by stimulation of the locus coeruleus in the ratJournal of Neural Transmission, 1993
- Comparison of the disposition and of the metabolic pattern of Reboxetine, a new antidepressant, in the rat, dog, monkey and manEuropean Journal of Drug Metabolism and Pharmacokinetics, 1991